Trial Completed: Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases (NCT04353609)
WHY IT MATTERS
If you have an autoimmune or inflammatory disease, this completed trial provides real-world evidence about COVID-19 risk in your population—information that can help you and your doctor make informed decisions about infection prevention and disease management.
Researchers completed a large study of 13,770 patients with chronic inflammatory diseases (like rheumatoid arthritis and other autoimmune conditions) to understand how COVID-19 affected them. The study, led by a hospital in France, was designed to track whether patients taking medications for their autoimmune diseases had worse outcomes if they caught COVID-19. This trial has now finished collecting data.
NCT ID: NCT04353609 Status: COMPLETED Conditions: Sars-CoV2, Chronic Inflammatory Rheumatism, Autoimmune Diseases Enrollment: 13770 Sponsor: University Hospital, Lille Summary: Since December 2019, an international outbreak of respiratory illnesses caused by SARS-CoV-2 called covid-19 has become a global challenge. In France, while the first cases were reported in January, more than 20 000 cases were confirmed at end of March. Early estimations from epidemiological data seem to show that 18-20% of patients with confirmed covid-19 are admitted in an intensive care unit (ICU). Patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-ra